BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 25276134)

  • 1. Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer.
    Pinto N; Black M; Patel K; Yoo J; Mymryk JS; Barrett JW; Nichols AC
    J Oncol; 2014; 2014():936285. PubMed ID: 25276134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
    Li Z; Zhang Y; Wang R; Zou K; Zou L
    Exp Ther Med; 2019 Oct; 18(4):2369-2377. PubMed ID: 31555347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular therapeutics for anaplastic thyroid cancer.
    Pozdeyev N; Rose MM; Bowles DW; Schweppe RE
    Semin Cancer Biol; 2020 Apr; 61():23-29. PubMed ID: 31991166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaplastic thyroid cancer: prevalence, diagnosis and treatment.
    Chiacchio S; Lorenzoni A; Boni G; Rubello D; Elisei R; Mariani G
    Minerva Endocrinol; 2008 Dec; 33(4):341-57. PubMed ID: 18923370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-dimensional genome landscape comprehensively reveals patterns of spatial gene regulation in papillary and anaplastic thyroid cancers: a study using representative cell lines for each cancer type.
    Zhang L; Xu M; Zhang W; Zhu C; Cui Z; Fu H; Ma Y; Huang S; Cui J; Liang S; Huang L; Wang H
    Cell Mol Biol Lett; 2023 Jan; 28(1):1. PubMed ID: 36609218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
    Smith N; Nucera C
    J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mutation profile of differentiated thyroid cancer coexisting with undifferentiated anaplastic cancer resembles that of anaplastic thyroid cancer but not that of archetypal differentiated thyroid cancer.
    Mika J; Łabaj W; Chekan M; Abramowicz A; Pietrowska M; Polański A; Widłak P
    J Appl Genet; 2021 Feb; 62(1):115-120. PubMed ID: 33222100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular aberrations and signaling cascades implicated in the pathogenesis of anaplastic thyroid cancer.
    Saini S; Maker AV; Burman KD; Prabhakar BS
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188262. PubMed ID: 30605717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
    Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
    Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
    [No Abstract]   [Full Text] [Related]  

  • 10. DURABLE RESPONSE IN A CASE OF METASTATIC ANAPLASTIC THYROID CANCER USING A COMBINATION OF TYROSINE KINASE INHIBITORS AND A CHECK POINT INHIBITOR.
    Lungulescu C; Croitoru VM; Lungulescu C; Croitoru A; Paul D
    Acta Endocrinol (Buchar); 2020; 16(2):236-241. PubMed ID: 33029242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
    Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
    [No Abstract]   [Full Text] [Related]  

  • 13. Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing.
    Tarasova VD; Tsai J; Masannat J; Hernandez Prera JC; Hallanger Johnson J; Veloski C; Agosto Salgado S; McIver B; Drusbosky LM; Chung CH
    Thyroid; 2024 Feb; 34(2):197-205. PubMed ID: 37962267
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
    Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
    Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
    Charles RP; Silva J; Iezza G; Phillips WA; McMahon M
    Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
    Xing M
    Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
    Kunstman JW; Juhlin CC; Goh G; Brown TC; Stenman A; Healy JM; Rubinstein JC; Choi M; Kiss N; Nelson-Williams C; Mane S; Rimm DL; Prasad ML; Höög A; Zedenius J; Larsson C; Korah R; Lifton RP; Carling T
    Hum Mol Genet; 2015 Apr; 24(8):2318-29. PubMed ID: 25576899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of
    Ibrahimpasic T; Xu B; Landa I; Dogan S; Middha S; Seshan V; Deraje S; Carlson DL; Migliacci J; Knauf JA; Untch B; Berger MF; Morris L; Tuttle RM; Chan T; Fagin JA; Ghossein R; Ganly I
    Clin Cancer Res; 2017 Oct; 23(19):5970-5980. PubMed ID: 28634282
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.